Pharmacokinetics of Intravenous Conivaptan in Subjects With Hepatic or Renal Impairment

Background Conivaptan is a non-peptide dual antagonist of vasopressin V 1A and V 2 receptors that is approved in the United States as an intravenous formulation for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients. The pharmacokinetics of intravenous conivaptan had n...

Ausführliche Beschreibung